Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5103486 | 0.91 | TACR3 (0.54) | TACR3TACR2 | |
| SCHEMBL4618529 | 0.90 | TACR3 (0.53) | TACR3TACR2 | |
| SCHEMBL5113313 | 0.90 | TACR3 (0.57) | TACR3TACR2 | |
| SCHEMBL5103809 | 0.86 | TACR3 (0.58) | TACR3TACR2 | |
| SCHEMBL14015203 | 0.86 | TACR3 (0.57) | TACR3TACR2 | |
| SCHEMBL14015204 | 0.83 | TACR3 (0.71) | TACR3TACR2 | |
| SCHEMBL5103841 | 0.83 | TACR3 (0.56) | TACR3TACR2 | |
| SCHEMBL4601759 | 0.81 | TACR3 (0.56) | TACR3TACR2 | |
| SCHEMBL4603512 | 0.80 | TACR3 (0.60) | TACR3TACR2 | |
| SCHEMBL5107299 | 0.80 | TACR3 (0.71) | TACR3TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | claimed |
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280949-A1 | Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators | KCNA3, KCNQ3, GPR3 | TACR3 8/4885TACR2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.